Core Viewpoint - TScan Therapeutics, Inc. is participating in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25, 2025, focusing on its T cell receptor-engineered T cell therapies for cancer treatment [1]. Company Overview - TScan Therapeutics is a clinical-stage biotechnology company dedicated to developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies aimed at treating cancer patients [3]. - The company's lead TCR-T therapy candidates are designed for patients with hematologic malignancies, specifically to prevent relapse after allogeneic hematopoietic cell transplantation, as part of the ALLOHA™ Phase 1 heme trial [3]. - TScan is expanding its ImmunoBank, a repository of therapeutic TCRs that target diverse antigens and are compatible with multiple HLA types, to create customized multiplex TCR-T therapies for various cancers, including the PLEXI-T Phase 1 solid tumor trial [3]. - The company is currently enrolling patients in both clinical programs [3]. Event Information - A webcast of the fireside chat will be accessible on the "Events and Presentations" section of TScan's website, with an archived replay available for 90 days post-event [2].

Core Viewpoint - TScan Therapeutics, Inc. (TCRX) is experiencing significant selling pressure but is positioned for a potential trend reversal due to being in oversold territory and positive earnings outlook from analysts [1]. Group 1: Stock Performance - TCRX has declined by 5.6% over the past four weeks, indicating a downward trend [1]. - The current Relative Strength Index (RSI) for TCRX is 25.67, suggesting that heavy selling may be exhausting itself [5]. Group 2: Analyst Sentiment - There is strong consensus among Wall Street analysts that TCRX will report better earnings than previously predicted, with a 0.9% increase in the consensus EPS estimate over the last 30 days [6]. - TCRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [7]. Group 3: Technical Indicators - The RSI is a momentum oscillator that helps identify oversold conditions, typically when the reading falls below 30 [2]. - The RSI assists investors in spotting potential entry opportunities when a stock is undervalued due to unwarranted selling pressure [3].

Core Viewpoint - TScan Therapeutics, Inc. has secured a significant investment of approximately $30 million from Lynx1 Capital Management LP, which reflects a 37% premium over the last closing price of its common stock, indicating strong investor confidence in the company's mission to develop TCR-T cell therapies for cancer treatment [1][5]. Company Overview - TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on T cell receptor (TCR)-engineered T cell (TCR-T) therapies aimed at treating cancer patients [5][10]. - The company is developing its lead TCR-T therapy candidates for hematologic malignancies and has ongoing clinical trials, including the ALLOHATM Phase 1 heme trial and the PLEXI-TTM Phase 1 solid tumor trial [10]. Financial Details - The investment involves the sale of pre-funded warrants to purchase up to 7,500,000 shares of voting common stock at a price of $4.00 per warrant, with an exercise price of $0.0001 per share [5]. - Following this financing, the company expects its cash resources to fund operations into the first quarter of 2027, extending its financial runway beyond previous estimates [9].

Company Overview - TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer treatment [5] - The company's lead TCR-T therapy candidates are aimed at treating hematologic malignancies and preventing relapse after allogeneic hematopoietic cell transplantation [5] - TScan is expanding its ImmunoBank, a repository of therapeutic TCRs, to provide customized multiplex TCR-T therapies for various cancers [5] Recognition and Workplace Culture - TScan has been recognized as one of the Top Places to Work in Massachusetts for the third consecutive year, reflecting its employee-centric values and exceptional workplace culture [3][2] - The recognition is based on a survey conducted by Energage, which collected confidential feedback from nearly 68,000 employees across 323 organizations in Massachusetts [3][2] - The survey evaluates employee opinions on various aspects such as company direction, management, work environment, and benefits [2] Leadership Statements - The CEO of TScan, Gavin MacBeath, emphasized the company's commitment to advancing its clinical-stage pipeline and acknowledged the hard work of the team in creating a positive workplace culture [3] - Ann Hargraves, Senior VP of Human Resources, highlighted the organization's progress over the past five years and the importance of a committed and unified team [3]

Core Viewpoint - TScan Therapeutics, Inc. reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of $0.28, indicating a positive earnings surprise of 10.71% [1] Financial Performance - The company posted revenues of $1.05 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 63.36%, and a decline from $3.89 million in the same quarter last year [2] - Over the last four quarters, TScan Therapeutics has surpassed consensus EPS estimates three times [2] Stock Performance - TScan Therapeutics shares have decreased by approximately 2.2% since the beginning of the year, contrasting with the S&P 500's gain of 25.8% [3] Future Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.28 on revenues of $6.19 million, and for the current fiscal year, it is -$1.17 on revenues of $10.15 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which TScan Therapeutics belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

TScan Therapeutics, Inc. (TCRX) shares soared 7.6% in the last trading session to close at $5.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.4% loss over the past four weeks.The company is developing its lead TCR-T therapy candidates, TSC-100 and TSC-101, in an early-stage study for treating patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. TScan is also deve ...

All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT with reduced intensity conditioning Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10, at 8:00 a.m. ET WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology c ...

WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6 – 10 in Houston, TX and virtually. Poster Presentation Details: Title: Disco ...

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 6.67%. A quarter ago, it was expected that this company would post a loss of $0.25 per share when it actually produced a loss of $0.32, delivering a surprise of -28%. Over the last four quarters, the company has ...

FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization On-track to report initial data from the solid tumor program and one-year data on initial patients in the ALLOHATM Phase 1 heme trial by the end of 2024 Cash, cash equivalents, and marketable securities continue to fund operations into the fo ...